A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

This study has been completed.

First Received on September 13, 2005. Last Updated on October 14, 2010 History of Changes

Sponsor:	Teva Pharmaceutical Industries
Information provided by:	Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:	NCT00203008

Purpose

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

Condition
Parkinson's Disease Malignant Melanoma

Study Type:	Observational
Official Title:	A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients

Resource links provided by NLM:

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease Perry syndrome

MedlinePlus related topics: Melanoma Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Teva Pharmaceutical Industries:

Enrollment:	2106
Study Start Date:	January 2003
Study Completion Date:	September 2003

Groups/Cohorts
Observational procedure Patients will be examined and any suspicious skin abnormalities will be biopsied

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients known to have Parkinson's Disease will be invited to join the study by their treating physicians as long as they are not taking investigational product.

Criteria

Inclusion Criteria:

Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent Patient must not be taking any investigational drug at the time of enrollment

Exclusion Criteria:

unconfirmed, undocumented Parkinson's disease unable to give consent taking any investigational product

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00203008

Sponsors and Collaborators

Teva Pharmaceutical Industries

Investigators

Study Director:

Bruce Schwartz, Ph.D.

Teva Neuroscience, Inc.

More Information

No publications provided

Responsible Party:	J. Michael Nicholas, PhD, Sr. Director, Teva Neuroscience
ClinicalTrials.gov Identifier:	NCT00203008 History of Changes
Other Study ID Numbers:	EP002
Study First Received:	September 13, 2005
Last Updated:	October 14, 2010
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Melanoma
Parkinson Disease
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue

Nevi and Melanomas
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on February 12, 2012